focus
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.
advertisement
AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
How to make Best Hospitals ratings actually useful for patients
Next article： How one medical school became remarkably diverse
Next article： How one medical school became remarkably diverse
